Argatroban and catheter-directed thrombolysis with alteplase for limb- and graft-threatening thromboses in a patient with a history of HIT

American Journal of Hematology

Volumn 84, Issue 4, 2009, Pages 251-253

  Maldonado, Angela ^a,b,c  

^a SACRED HEART MEDICAL CENTER   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALLOPURINOL; ALTEPLASE; ARGATROBAN; ATENOLOL; CALCIUM CARBONATE; CARVEDILOL; CIPROFLOXACIN; CREATININE; FERROUS SULFATE; FISH OIL; FONDAPARINUX; FUROSEMIDE; GLIPIZIDE; HEPARIN; METRONIDAZOLE; MULTIVITAMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANTOPRAZOLE; PREDNISONE; TACROLIMUS; TAMSULOSIN; WARFARIN; ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; PIPECOLIC ACID DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR;

ABNORMAL RESPIRATORY SOUND; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING RATE; CASE REPORT; CATHETER DIRECTED THROMBOLYSIS; CREATININE BLOOD LEVEL; CYANOSIS; DEEP VEIN THROMBOSIS; DIAPHORESIS; DIARRHEA; DIVERTICULITIS; DIZZINESS; GRAFT OCCLUSION; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; LEG EDEMA; LEG THROMBOSIS; LEUKOCYTE COUNT; LUNG EMBOLISM; MALE; METABOLIC ACIDOSIS; NAUSEA; OXYGEN SATURATION; PAIN; PRIORITY JOURNAL; PULSE RATE; THROMBOCYTOPENIA; VOMITING; BLOOD; CATHETERIZATION; CHEMICALLY INDUCED DISORDER; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DRUG COMBINATION; DRUG CONTRAINDICATION; FEMORAL VEIN; FIBRINOLYTIC THERAPY; GENETICS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; ILIAC VEIN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIA; KIDNEY; KIDNEY TRANSPLANTATION; KIDNEY VEIN; METHODOLOGY; POPLITEAL VEIN; POSTOPERATIVE COMPLICATION; PROTEIN S DEFICIENCY; THROMBOPHILIA; VASCULARIZATION; VEIN THROMBOSIS; VENA CAVA FILTER;

AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTICOAGULANTS; CATHETERIZATION; DRUG THERAPY, COMBINATION; FEMORAL VEIN; HEPARIN; HUMANS; ILIAC VEIN; INFUSIONS, INTRAVENOUS; ISCHEMIA; KIDNEY; KIDNEY TRANSPLANTATION; MALE; PIPECOLIC ACIDS; POPLITEAL VEIN; POSTOPERATIVE COMPLICATIONS; PROTEIN S DEFICIENCY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RENAL VEINS; THROMBOLYTIC THERAPY; THROMBOPHILIA; TISSUE PLASMINOGEN ACTIVATOR; VENA CAVA FILTERS; VENOUS THROMBOSIS; WARFARIN;

EID: 64549098110     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21367     Document Type: Article

References (12)

1. Hirsh J, Guyatt G, Albers GW, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):110S-112S; Erratum in: Chest 2008;134:473.
2. Cathflo™ Activase® [Alteplase] [package insert]. South San Francisco, CA: Genentech, Inc.; 2001.
3. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion - A consensus document. J Vasc Interv Radiol 2003;14:S337-S349.
4. Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
5. Turba UC, Bozlar U, Simsek S. Catheter-directed thrombolysis of acute lower extremity arterial thrombosis in a patient with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2007;70:1046-1050.
6. Yamada K, Tsuji H, Kimura S, et al. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. Thromb Res 2003;109:55-64.
7. Boeve TJ, Reed GL, de Oliveira NC, et al. Comparison of argatroban and hirudin for the reperfusion of thrombotic arterial occlusion by tissue plasminogen activator. J Thromb Thrombolysis 1998;6:103-108.
8. Serebruany VL, Jang IK, Giugliano RP, et al. A randomized, blinded study of two doses of Novastan(R) (brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the myocardial infarction using Novastan(R) and T-PA (MINT) study. J Thromb Thrombolysis 1998;5:49-52.
9. Valji K, Arun K, Bookstein JJ. Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis. J Vasc Interv Radiol 1995;6:91-95.
10. LaMonte MP, Stallmeyer MJ. Acute ischemic stroke successfully treated using sequenced intravenous and intra-arterial thrombolysis and argatroban anticoagulation: A case study. J Thromb Thrombolysis 2004;17:151-156.
11. Wong CK, White HD. Direct antithrombins: Mechanisms, trials, and role in contemporary interventional medicine. Am J Cardiovasc Drugs 2007;7:249-257.
12. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004;38:25-29. (Pubitemid 38018000)